Customers Who Bought This Product Also Bought
The Ultimate Joint Function Enhancer*
One in five (21%) adults in the United States report having been diagnosed with arthritis.1 By 2030, an estimated 67 million Americans aged 18 years or older are projected to have arthritis. The prevalence of arthritis is increasing and the research supporting a nutritional approach to arthritis management is becoming stronger.
Joint RescueTM is a clinically-tested joint support formulation for those suffering from pain and joint restriction present with arthritis. Joint Rescue’sTM is unique blend of four synergistic compounds formulated to support and heal compromised joints.
Traditionally, non-steroidal anti-inflammatory drugs (NSAIDS) have been the common choice for symptom relief. Statistics put annual deaths from NSAIDS at 20,000 and the World Journal of Gastroenterology states that 10% of drug-induced liver damage is caused from NSAIDs. In contrast, Joint Rescue uniquely supplies the full range of joint-building blocks without harmful side effects.
According to research published in Clinical Drug Investigations, the unique combination of glucosamine and MSM is more effective against osteoarthritis than either individual nutrient alone.2 The individual nutrients did show a reduction in pain and swelling; however, the combined formulation was more effective than MSM or glucosamine alone in reducing pain and improving overall joint function. “It can be concluded,” the researchers said, “that the combination of MSM with glucosamine provides better and more rapid improvement in patients with osteoarthritis.”
MSM is added to Joint RescueTM because it is a naturally occurring sulfur compound used to synthesize glutathione which will protect joints from oxidation damage. Utilize Joint RescueTM, the ultimate joint protection and repair product, to keep mobile, flexible and pain-free.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
- Murphy, Louise, and Charles G. Helmick. "The impact of osteoarthritis in the United States: a population-health perspective: A population-based review of the fourth most common cause of hospitalization in US adults." Orthopaedic Nursing 31.2 (2012): 85-91.
Usha, P. R., and M. U. R. Naidu. "Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis." Clinical drug investigation 24.6 (2004): 353-363.
As a dietary supplement, take three (3) capsules daily or as directed by your healthcare professional. For acute concerns, it may be beneficial to take three (3) capsules twice daily until comfort is fully restored.
As with any dietary supplement, consult your healthcare practitioner before using this product, especially if you are pregnant, nursing, anticipate surgery, take any medication or are otherwise under medical supervision. Do not use this product if you are allergic to shellfish.
Formulated To Be Free of Allergens Derived From:
Wheat, soy, dairy, eggs, fish, tree nuts, peanuts, artificial preservatives, sweeteners, color and flavors.
Contains: Shellfish (shrimp, crab and/or lobster)
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
References and Research Abstracts Supporting Joint Rescue
1. Raskin JB. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med 1999; 106(5B):3S- 12S
2. Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective-1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 1998; 51:8-16
3. Simon LS. The evolution of arthritis antiinflammatory care: where are we today? J Rheumatol 1999; 26 Suppl56:11-7
4. Sheild MJ. Anti-inflammatory drugs and their effects on cartilage synthesis and renal function. Eur J Rheumatol Inflamm 1993; 13(1):7-16
5. Field TS, Gurwitz JH, Glynn RJ, et al. The renal effects of nonsteroidal anti-inflammatory drugs in older people: findings from the Established Populations for Epidemiologic Studies of the Elderly. J Am Geriatr Soc 1999; 47(5):507-11
6. Blantz RC. Acetaminophen: acute and chronic renal function. Am J Kidney Dis 1996; 28(Suppl 1):S3-6
7. Roach JA, Stacey B. Acetaminophen toxicity. Orthop Nurs 1997; 16(3):49-53
8. Brandt KD. Effects of nonsteroidal anti-inflammatory drugs on chondrocyte metabolism in vitro and in vivo. Am J Med 1987; 83(5A):29-34
9. Redini F, Mauviel A, Loyau G, Pujol JP. Modulation of extracellular matrix metabolism in rabbit articular chondrocytes and human rheumatoid synovial cells by the non-steroidal anti-inflammatory drug etodolac. II: Glycosaminoglycan synthesis. Agents Actions 1990; 31(3-4):358-67
10.Dekel S, Falconer J, Francis MJ.The effects of anti-inflammatory drugs on glycosaminoglycan sulphation in pig cartilage. Prostaglandins Med 1980; 4(3):133-40
11. Hugenberg ST, Brandt KD, Cole CA. Effect of sodium salicylate, aspirin, and ibuprofen on enzymes required by the chondrocyte for synthesis of chondroitin sulfate. J Rheumatol 1993; 20(12):2128-33
12.Roden L.Effect of hexosamine on the synthesis of chondroitin sulpheric acid in vitro. Arkiv For Kemi 1956; 10(23):345-353
13. Karzel K, Domenjoz R. Effects of Hexosamine Derivatives and Uronic Acid Derivatives on Glycosaminoglycane Metabolism of Fibroblast Cultures. Pharmacology 1971; 5:337-345
14. Kim JJ, Conrad HE. Effect of D-Glucosamine Concentration on the Kinetics of Mucopolysaccharide Biosynthesis in Cultured Chick Embryo Vertebral Cartilage. J Biol Chem 1974; 249(10):3091-7
15. Vidal y Plana RR, Bizzarri D, Rovati AL. Articular Cartilage Pharmacology: I. In vitro studies on glucosamine and non steroidal antiinflammatory drugs. Pharmacol Res Com 1978; 10(6):557-569
16. Setnikar I, Giachetti C, Zanolo G. Absorption, distribution and excretion of radioactivity after a single inravenous or oral administration of [14C] glucosamine to the rat. Pharmatherapeutica 1984; 3(8):538-50
17. Setnikar I, Giacchetti C, Zanolo G. Pharmacokinetics of glucosamine in the dog and in man. Arzneimittelforschung 1986; 36(4):729-35
18. Setnikar I, Palumbo R, Canali S, Zanolo G. Pharmacokinetics of glucosamine in man. Arzneimittelforschung 1993; 43(10); 1109-1319. McCarty MF
19. Enhanced synovial production of hyaluronic acid may explain rapid clinical response to high-dose glucosamine in osteoarthritis. Med Hypothesis 1998; 50(6):507-10
20.Vaz AL. Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients. Current Med Res and Opinion 1982; 8:145
21. Tapadinhas MJ, Rivera IC, Bignamini AA. Oral glucosamine sulphate in the management of arthrosis: Report on a multi-center open investigation in Portugal. Pharmatherapeutica 1982; 3:157
22. Vajaradul Y. Double-blind clinical evaluation of intra-articular glucosamine in outpatients with gonarthrosis. Clinical Therapeutical 1981; 3(5):
23. Pujalte JM, Llavore EP,Ylescupidez FR. Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis. Current Med Res and Opinion 1980; 7:110
24. Crolle G, D’Estes E. Glucosamine sulphate for the management of arthrosis: a controlled clinical investigation. Curr Med Res Opinion 1980; 7:104
25. D’Ambrosia, Casa B, et al. Glucosamine Sulphate: a controlled clinical investigation in arthrosis. Pharmatherapeutica 1981; 2:504
26. Drovanti A, Bignamini AA,Rovati AL. Therapeutic activity of oral glucosamine sulfate in osteoarthrosis: a placebo-controlled double-blind investigation. Clinical Therapeutics 1980; 3(4)
27. McCarty MF,Glucosamine may retard atherogenesis by promoting endothelial production of heparin sulfate proteoglycans. Med Hypothese 1997; 48(3):245-51
28. Qiu GX, Gao SN, Giacovelli G et al. Efficacy and safety of glucosamine sulfate versus ibuprofen in patient with knee osteoarthritis. Arzneimittelforschung 1998; 48(5):469-74
29. Bassleer C, Rovati L, Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cartilage 1998; 6(6):427-34
30. Gottlieb MS. Conservative management of spinal osteoarthritis with glucosamine sulfate and chiropractic treatment. J Manipulative Physiol Ther 1997; 20(6):400-14
31.da Camara CC,Dowless GV.Glucosamine sulfate for osteoarthritis. Ann Pharmacother 1998;
32(5):580- 7 32. Russell AL.Glucosamine in osteoarthritis and gastrointestinal disorders: an exemplar of the need for a paradigm shift. Med Hypothesis 1998; 51(4):347-9
33. Barclay TS, Tsourounis C, McCart GM. Glucosamine. Ann Pharmacother 1998; 32(5):574-9
34. Palmieri L, Conte A, Giovannini L, et al. Metabolic fate of exogenous chondroitin sulfate in the experimental animal. Arzneimettelforschung 1990; 40(3):319-23
35. Conte A, Volpi N, Palmieri L, et al. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimittelforschung 1995; 45(8):918-25
36. Conte A, Palmieri L, Segnini D, Ronca G. Metabolic fate of partially depolymerized chondroitin sulfate administered to the rat. Drugs Exp Clin Res 1991; 17(1):27-33
37. Mazieres B, Loyau G, Menkes CJ, et al. Chondroitin sulfate in the treatment of gonarthrosis and coxarthrosis. 5-month result of a multicenter double-blind controlled prospective study using placebo. Rev Rhum Mal Osteoartic 1992; 59(7-8):466-472
38. Leeb BF, Petera P, Neumann K. Results of a multicenter study of chondroitin sulfate (Condrosulf) use in arthroses of the finger, knee and hip joints.Wien Med Wochenschr 1996; 146(24):609-614
39. Morreale P, Manopulo R, Galati M, et al. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996; 23(8):1385-91
40. Uebelhart D, Thonar EJ, Delmas PD, et al. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 1998; 6 (Suppl A):39-46
41. Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 1998; 6 (Suppl A):31-36
42.Verbruggen G,Goemaere S,Veys EM. Chondroitin sulfate: S/DMOAD (structure/disease modifying antiosteoarthritis drug) in the treatment of finger joint OA.
Osteoarthritis Cartilage 1998; 6 (Suppl A):37-843. Bourgeois P, Chales G, Dehais J, et al. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400 mg/day vs placebo. Osteoarthritis Cartilage 1998; 6 (Suppl A):25-30
44. Malaise M, Marcolongo R, Uebelhart D, Vignon E. Efficacy and tolerability of 800 mg oral Chondroitin 4&6 sulfate in the treatment of knee osteoarthritis: a randomised, double-blind, multicentre study versus placebo. Litera Rheumatologica 1999; 24:31-42
45. Conrozier T. Anti-arthrosis treatments: efficacy and tolerance of chondroitin sulfates. Presse Med 1998; 27(36):1862-5
46. Ronca F,Palmieri L,Panicucci P,Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 1998; 6 (Suppl A):14-21
47.Kelly GS.The role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease. Altern Med Rev 1998; 3(1):27-39
48.Deal CL,Moskowitz RW.Neutraceuticals as therapeutic agents in osteoarthritis.The role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Rheum Dis Clin North Am 1999; 25(2):379-95
49. Leffler CT, Philippi AF, Leffler SG, et al. Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study. Mil Med 1999; 164(2):85-91
50. Rizzo R, Grandolfo M, Godeas C, et al. Calcium, sulfur, and zinc distribution in normal and arthritic articular equine cartilage: a synchrotron radiation-induced X-ray emission (SRIXE) study. J Exp Zool 1995; 273(1):82-6
51. di Padova C. S-adenosylmethionine in the treatment of osteoarthritis.Review of the clinical studies.Am J Med 1987; 83(5A):60-5 52. Maccagno A, Di Giorgio EE, Caston OL, Sagasta CL. Double-blind controlled clinical trial of oral Sadenosylmethionine versus piroxicam in knee osteoarthritis. Am J Med 1987; 83(5A):72-7
53. Caruso I, Pietrogrande V. Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease. Am J Med 1987; 83(5A):66-71
54. Glorioso S, Todesca S, Mazzi A, et al. Double-blind multicentre study of the activity of Sadenosylmethionine in hip and knee osteoarthritis. Int J Clin Pharmacol Res 1985; 5(1):39-49
55.Vetter G. Double-blind comparative clinical trial with S-adenosylmethionine and indomethacin in the treatment of osteoarthritis. Am J Med 1987; 83(5A):78-80
56. Konig B. A long-term (two year) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis. Am J Med 1987; 83(5A):89-94
57. Harmand MF, Vilamitjana J, Maloche E, et al. Effects of S-adenosylmethionine on human articular chondrocyte differentiation. An in vitro study. Am J Med 1987; 83(5A):48-54
58. Gualano M, Berti F, Stramentinoli G. Anti-inflammatory activity of S-adenosyl-L-methionine in animal models: possible interference with the eicosanoid system. Int J Tissue React 1985; 7(1):41-6
59.Evans MS,Reid KH,Sharp JB Jr.Dimethylsulfoxide (DMSO) blocks conduction in peripheral nerve C fibers: a possible mechanism of analgesia. Neurosci Lett 1993; 150(2):145-8
60.Waddell PJ, Lawson SN. The C-fibre conduction block caused by capsaicin on rat vagus nerve in vitro. Pain 1989; 39(2):237-42
61. Eberhardt R, Zwingers T,Hofmann R. DMSO in patients with active gonarthrosis.A double-blind placebo controlled phase III study. Fortschr Med 1995; 113(31):446-50
62. Jacob SW, Lawrence RM, Zucker M. The Miracle of MSM. 1999.G.P. Putnam’s Sons; New York, NY
63. Murav’ev IuV, Venikova MS, Pleskovskaia GN. Effect of dimethyl sulfoxide and dimethyl sulfone on a destructive process in the joints of mice with spontaneous arthritis. Patol Fiziol Eksp Ter 1991; 2:37-39
64. Schwartz ER. The modulation of osteoarthritic development by vitamin C and E. Int J Vitam Nutr Res Suppl 1984; 26:141-6
65. Bolze MS, Reeves RD, Lindbeck FE, et al. Influence of manganese on growth, somatomedin and glycosaminoglycan metabolism. J Nutr 1985; 115(3):352-8
66.Yang P, Klimis-Tavantzis DJ. Effects of dietary manganese on arterial glycosaminoglycan metabolism in Sprague-Dawley rats. Biol Trace Elem Res 1998; 64(1-3):275-88
67. Masse PG, Ziv I, Cole DE, et al. A cartilage matrix deficiency experimentally induced by vitamin B6 deficiency. Proc Soc Exp Biol Med 1998; 217(1): 97-103
68. Talent JM,Gracy RW. Pilot study of oral polymeric N-acetyl-D-glucosamine as a potential treatment for patients with osteoarthritis. Clin Ther 1996; 18(6):1184-90